Are Fees The New Rebates? PhRMA Highlights Shifts In PBM Practices As House Tees Up Reform Vote

Pharmacy benefit managers are increasingly making money off new types of fees tied to list prices, drug industry lobby says, highlighting importance of delinking all PBM compensation from the cost of medicines. Most Congressional proposals in play do not include delinkage provision.

stick shift
PBM profit sources have shifted, new PhRMA-commissioned report says. • Source: Shutterstock

US brand drug industry trade group PhRMA is using the results of new research commissioned by the lobby to double down on its push to delink all pharmacy benefit manager’s compensation from the price of drugs, emphasizing that any such provisions must be crafted broadly to ensure they captures new fees PBMs have implemented outside of the more well-known rebates extracted from drug manufacturers.

The 18 September report by healthcare equity research firm Nephron shows a shift in the proportion of profits PBMs...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access